Holen Sie sich die Stockscreener-App
2.26
0.44%
-0.01
Handel nachbörslich:
2.27
0.01
+0.44%
Xbiotech Inc Aktie (XBIT) Neueste Nachrichten
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Balance Sheet - TradingKey
XBIT|XBiotech Inc|Price:2.260|Chg%:-0.010 - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT|XBiotech Inc|Price:2.270| - TradingKey
XBiotech, Inc. Actuals & Estimates (FWB:4XB) - TradingView
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech Inc. Revenue Breakdown – NASDAQ:XBIT - TradingView
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MSN Money - MSN
XBiotech (XBIT) Holds Steady at $2.29 as Range-Bound Trading ContinuesIPO Entry Watch - dars.gov.et
XBiotech Inc. (XBIT) Slides 2.97% as Shares Approach Key Support at $2.18Pairs Trade - dars.gov.et
XBiotech focuses on antibody pipeline as biotech sector evolves - Ad-hoc-news.de
ETFs Investing in XBiotech, Inc. Stocks - TradingView
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech Inc. (XBIT) Holds Steady at $2.33 as Key Support and Resistance Levels ConvergeVolume Dry Up - dars.gov.et
XBiotech, Inc. Actuals & Estimates (LS:A14QF1) - TradingView
XBiotech, Inc. Actuals & Estimates (MUN:4XB) - TradingView
Price to earnings forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT) - TradingView
Price to sales forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (DUS:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (BX:4XB) - TradingView
Enterprise value to revenue forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BOATS:XBIT) - TradingView
Price to book forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
Enterprise value to EBIT forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech to commence V-SPINE trial enrolment for vilamakitug - MSN
XBiotech (XBIT) Dips 2.53% as Shares Test Support Near $2.19Motive Wave - dars.gov.et
XBiotech Inc. (XBIT) Nears Key Support After 2.5% DeclineAdvance Decline Volume - dars.gov.et
XBiotech Inc. (XBIT) Declines: Testing Key Support Levels After 2.53% DropHigh Beta Stocks - dars.gov.et
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBIT Earnings Overview 2026-06-16Profit Warning Alert - dars.gov.et
XBiotech Receives Authorization for V-SPINE Trial - Intellectia AI
XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondy - AD HOC NEWS
XBiotech (XBIT) Receives FDA Nod for V-SPINE Study - GuruFocus
XBiotech clears FDA review for axial spondyloarthritis study - Investing.com
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - Yahoo Finance UK
XBiotech Inc. (XBIT) Holds Near Support Amidst Minor DeclinesDescending Triangle - newsline.com
XBIT Should I Buy - Intellectia AI
XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update - Ad-hoc-news.de
XBiotech Inc. (XBIT) Slips 2.27% as Stock Tests Key Support LevelsMotive Wave - The Legal Advocate
XBITXBiotech Inc Dividends - Finviz
XBiotech Inc. (XBIT) Edges Higher, Approaching Key Resistance at $2.56Trading Ideas - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher on Modest Volume, Tests Resistance Near $2.58Composite Profile - The Legal Advocate
XBiotech (XBIT) Edges Lower as Stock Tests Key Support LevelFloat Adjusted Cap - dars.gov.et
XBIT | XBiotech Inc Insider Trading - Quiver Quantitative
XBiotech stock (US9840001002): Clinical-stage biotech stays in focus - AD HOC NEWS
XBiotech: Q1 Earnings Snapshot - Stamford Advocate
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):